Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120348) titled 'A study on the clinical application value of assisting in the diagnosis of prostate cancer and risk stratification by detecting human PCA3 gene expression prior to biopsy' on March 12.
Study Type: Diagnostic test
Study Design:
Cross-sectional
Primary Sponsor: The First Medical Center of Chinese People's Liberation Army General Hospital
Condition:
Prostate cancer
Intervention:
Gold Standard:Prostate needle biopsy pathology
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2025-10-20
Target Sample Size: Target condition:60;Difficult condition:120
Countries of Recruitment:
China
T...